Udtog, Noraisa .

HRN: 23-32-03  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/09/2023
CO-AMOXICLAV 625MG (TAB)
08/09/2023
08/16/2023
ORAL
625
BID
RMLE
Checking Final Appropriateness 

Indication:  Prophylaxis    Type of Infection:  Prophylaxis    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Intervention



Type of Intervention done:

                    

           


Acceptance: